Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2024 | Reducing steroid usage in the treatment of lower-risk GvHD

James Ferrara • 16 Apr 2024
EBMT 2024
General

James Ferrara, MD, DSc, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, discusses how clinicians can improve the treatment of graft-versus-host disease (GvHD). GvHD is becoming increasingly lower-risk, so Dr Ferrara recommends minimizing steroid use. He proposes using risk stratification with clinical features and biomarkers to identify lower-risk patients suitable for lower steroid doses. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

I hold a patent for serum biomarkers of acute GVHD which is licensed and for which I receive royalties.

More from James Ferrara

1:02
The MAGIC model: a day 14 endpoint for acute GvHD clinical trials
James Ferrara • 16 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes at the onset of GvHD
James Ferrara • 16 Apr 2024
0:46
ST2 and REG3α as predictive biomarkers for GvHD
James Ferrara • 24 Apr 2023
1:54
A novel clinical trial endpoint for acute GvHD
James Ferrara • 24 Apr 2023

Related Videos

4:09
Veno-occlusive disease as a post-transplant complication of HSCT
Mohamad Mohty • 17 Apr 2024
1:56
Addressing access inequality in CAR-T therapies
Francesca Del Bufalo • 15 Apr 2024
1:34
The future role of AI models in hematology and the need for high-quality data sets
Thomas Coats • 29 Apr 2024
6:38
Key papers in cardio-oncology from 2023 of relevance to hematologists
Alexander Lyon • 25 Apr 2024
The content of VJHemOnc is intended for healthcare professionals